Biogen Inc. (BVMF:BIIB34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 168.14B +54.5% |
| Revenue (ttm) | 51.95B +0.3% |
| Net Income | 4.32B -45.5% |
| EPS | 29.21 -46.1% |
| Shares Out | n/a |
| PE Ratio | 38.89 |
| Forward PE | 16.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Open | 188.29 |
| Previous Close | n/a |
| Day's Range | 188.29 - 188.29 |
| 52-Week Range | 120.36 - 191.00 |
| Beta | 0.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen price target raised to $260 from $240 at RBC Capital
TRBC Capital raised the firm’s price target on Biogen (BIIB) to $260 from $240 and keeps an Outperform rating on the shares. The firm says the litifilimab data in Q4…
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
Eisai (ESAIY) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early Alzheimer’s disease in adults with mild c...
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
Eisai (ESAIY) and Biogen (BIIB), announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early Alzheimer’s disease in adults with mild ...
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloi...
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 /PRNewsw...
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform with a $300 price target
Wolfe upgrades Biogen to Outperform on late-stage pipeline
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform with a $300 price target The readouts for both litifilimab and felzartamab are “relative de-risked” and underappreciated at curren...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Biogen completes acquisition of RayThera
Biogen (BIIB) announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. “The ac...
Biogen Completes Acquisition of RayThera Inc.
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on dis...
Biogen price target raised to $241 from $221 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Biogen (BIIB) to $241 from $221 and keeps an Outperform rating on the shares.
Biogen price target raised to $215 from $200 at Citi
Citi raised the firm’s price target on Biogen (BIIB) to $215 from $200 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology space post…
Biogen price target raised to $231 from $222 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Biogen (BIIB) to $231 from $222 and keeps an Equal Weight rating on the shares.
Biogen price target raised to $251 from $237 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Biogen (BIIB) to $251 from $237 and keeps a Buy rating on the shares. The firm revisited its penetration assumption across Leqembi,…
Biogen price target lowered to $240 from $242 at RBC Capital
RBC Capital lowered the firm’s price target on Biogen (BIIB) to $240 from $242 and keeps an Outperform rating on the shares. The company reported a very solid commercial quarter,…
Biogen price target raised to $240 from $225 at UBS
UBS raised the firm’s price target on Biogen (BIIB) to $240 from $225 and keeps a Buy rating on the shares.
Biogen price target raised to $215 from $201 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Biogen (BIIB) to $215 from $201 and keeps a Neutral rating on the shares. Overall, the firm sees a solid…
Biogen price target raised to $219 from $215 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Biogen (BIIB) to $219 from $215 and keeps a Neutral rating on the shares. Biogen’s Q2 was “solid” by most…
Biogen price target raised to $225 from $215 at TD Cowen
TD Cowen analyst Phil Nadeau raised the firm’s price target on Biogen (BIIB) to $225 from $215 and keeps a Buy rating on the shares. The firm noted they reported…
Biogen price target raised to $248 from $245 at Canaccord
Canaccord raised the firm’s price target on Biogen (BIIB) to $248 from $245 and keeps a Buy rating on the shares. The firm noted they are pleased by yet another…
Biogen Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, driven by the expanding growth portfolio and successful integration of Apellis products. The company raised its full-year guidance, highlighted robust late-stage pipeline progress, and expects continued top- and bottom-line growth, with key data readouts and product launches ahead.
Biogen Slides: Q2 2026
Biogen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Biogen Earnings release: Q2 2026
Biogen released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Biogen Quarterly report: Q2 2026
Biogen has published its Q2 2026 quarterly earnings report on July 29, 2026.
Biogen Cuts FY Adjusted View as Profit Declines
Biogen's second-quarter profit plummeted and the biopharmaceutical company cut its full-year adjusted earnings forecast.